SCHEDULE 13G/A: Lombard Odier Asset Management Discloses 7.6% Stake in Silence Therapeutics plc
Beneficial Ownership Report
Lombard Odier Asset Management (USA) Corp has filed an amended Schedule 13G, reporting a beneficial ownership of 7.6% in Silence Therapeutics plc as of December 31, 2024.
Summary
- Lombard Odier Asset Management (USA) Corp, acting as an investment advisor, has filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership in Silence Therapeutics plc.
- As of December 31, 2024, Lombard Odier Asset Management beneficially owns an aggregate of 10,713,627 Ordinary Shares of Silence Therapeutics plc.
- This ownership represents 7.6% of the company's outstanding shares.
- The calculation of the percentage is based on 141,644,488 Shares issued and outstanding as of September 30, 2024, as disclosed by Silence Therapeutics plc in a Form 6-K filed on November 14, 2024.
- The total beneficial ownership includes 3,571,209 American Depositary Shares (ADSs), with each ADS convertible into three Ordinary Shares.
- Lombard Odier Asset Management holds shared voting power and shared dispositive power over all 10,713,627 shares, with no sole voting or dispositive power.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without expressing positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- NA
Negatives
- NA
Risks
- No specific risks related to the issuer's operations or financial health are disclosed in this beneficial ownership report, as it primarily focuses on the reporting person's ownership stake.
Future Outlook
This document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding Silence Therapeutics plc's future outlook.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investment advisor in a publicly traded biotechnology company. It reflects an investment decision by Lombard Odier Asset Management but does not provide broader industry trend analysis or competitive insights.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- This filing informs shareholders and the market about a significant ownership stake held by Lombard Odier Asset Management, which can influence market perception and trading activity.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | Date as of which 141,644,488 Shares were issued and outstanding, used for percentage calculation. |
| 2024-11-14 | Date Silence Therapeutics plc filed its Report of Foreign Private Issuer on Form 6-K, disclosing the number of outstanding shares. |
| 2024-12-31 | Date of event which requires the filing of this statement (beneficial ownership position). |
| 2025-02-11 | Date the Schedule 13G Amendment No. 5 was signed by Lombard Odier Asset Management (USA) Corp. |
Keywords
Silence Therapeutics plc, Lombard Odier Asset Management, Schedule 13G, Beneficial Ownership, SEC Filing, Ordinary Shares, American Depositary Shares, Investment Advisor, Shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.